Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A trial to investigate middle-east respiratory syndrome coronavirus vaccine for compassionate use

Next Previous
Trial Profile

A trial to investigate middle-east respiratory syndrome coronavirus vaccine for compassionate use

Status: Planning
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 29 Dec 2014

Print Profile Download Citation

At a glance

  • Drugs Middle-East respiratory syndrome coronavirus vaccine Organic Vaccines (Primary)
  • Indications Middle East respiratory syndrome coronavirus
  • Focus Therapeutic Use

    • Most Recent Events

    • 29 Dec 2014 New trial record
    • 17 Nov 2014 According to an Organic Vaccines media release, the company is completing the necessary documentation to file an authorization for compassionate use of its Monoclonal Antibodies from the WHO.

Trial Overview

Purpose

This compassionate use trial will investigate the efficacy and safety of middle-east respiratory syndrome coronavirus vaccine.

Comments

According to an Organic Vaccines media release, the company is completing the necessary documentation to file an authorization for compassionate use of its Monoclonal Antibodies from the WHO.

Diseases Treated

Indication Qualifiers Patient Segments
Middle East respiratory syndrome coronavirus prevention -

Subjects

  • Subject Type patients
  • Sex male & female
  • Age Group adult

Patient Inclusion Criteria

-Patients with middle-east respiratory syndrome coronavirus infection.

Trial Details

Organisations

  • Affiliations Organic Vaccines

Trial Dates

  • Initiation Dates

    Planned : 01 Apr 2015

Other Details

  • Design prospective
  • Phase of Trial Clinical Phase Unknown
  • Location Saudi Arabia
  • Focus Therapeutic Use

Interventions

Drugs Route Formulation
Middle-East respiratory syndrome coronavirus vaccine Organic VaccinesPrimary Drug
-
-

Middle-East respiratory syndrome coronavirus vaccine

Trial Centres

Centres

Download Data (CSV)
Centre Name Location Trial Centre Country
Organic Vaccines
-
-

+ Lead Centre

Trial History

Event Date Event Type Comment
29 Dec 2014 New trial record New trial record Updated 29 Dec 2014
17 Nov 2014 Other trial event According to an Organic Vaccines media release, the company is completing the necessary documentation to file an authorization for compassionate use of its Monoclonal Antibodies from the WHO. Updated 29 Dec 2014

References

  1. Organic-Vaccines. Organic Vaccines Plc - Agreements with National Institutes of Health and National Cancer Institute. Media-Rel 2014;.

    Media Release

  2. Organic Vaccines Plc. Organic Vaccines Plc - Agreements with National Institutes of Health and National Cancer Institute - 17 November 2014. Media-Rel 2014;.

    Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG
Legal
Back to top